Chemical Component Summary

NameCLINDAMYCIN
Identifiers(1R,2S,4R)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide
FormulaC18 H33 Cl N2 O5 S
Molecular Weight424.98
TypeNON-POLYMER
Isomeric SMILESCCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
InChIInChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1
InChIKeyKDLRVYVGXIQJDK-AWPVFWJPSA-N

Chemical Details

Formal Charge0
Atom Count60
Chiral Atom Count9
Chiral AtomsC1, C11, C13, C2, C3, C4, C5, C7, C8
Bond Count61
Aromatic Bond Count0
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB01190 Different stereochemistry
NameClindamycin
Groups
  • approved
  • vet_approved
DescriptionClindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Synonyms
  • 7-CDL
  • 7(S)-Chloro-7-deoxylincomycin
  • Cleocin (tn)
  • Clindamicina
  • Clindamycin
Salts
  • Clindamycin hydrochloride
  • Clindamycin palmitate hydrochloride
  • Clindamycin phosphate
Brand Names
  • Acanya
  • Apo-clindamycin
  • Auro-clindamycin
  • Ava-clindamycin
  • Benzaclin
Affected OrganismEnteric bacteria and other eubacteria
IndicationFor the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
PharmacologyClindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal.
Mechanism of actionSystemic/vaginal clindamycin inhibits protein synthesis of bacteria by binding to the 50S ribosomal subunits of the bacteria. Specifically, it binds primarily to the 23s RNA subunit. Topical clindamycin reduces free fatty acid concentrations on the skin and suppresses the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles.
Route of administration
  • Intramuscular; Intravenous
  • Intravenous
  • Oral
  • Topical
  • Vaginal
Categories
  • Anti-Acne Preparations
  • Anti-Acne Preparations for Topical Use
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antiinfectives for Treatment of Acne
ATC-Code
  • J01FF01
  • G01AA10
  • D10AF51
  • D10AF01
AHFS-Code
  • 08:12.28.20
  • 84:04.04
CAS number18323-44-9

Drug Targets

NameSequence SearchPharmacological ActionActions
50S ribosomal protein L10MALNLQDKQAIVAEVSEVAKGALSAVVADSRGVTVDKMTELRKAGREAGV...yesinhibitor
yesinhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682